Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome

Parameter

Placebo

Inhaled NO

P Value

Age, years

N

41

51

 
 

Mean ± SD

47.8 ± 16.7

45.3 ± 15.3

0.494

 

Range

18.4 - 84.0

16.8 - 77.9

 

Sex, n (%)

Male

19 (46%)

25 (49%)

0.836

 

Female

22 (54%)

26 (51%)

 

Race, n (%)

Caucasian

35 (85%)

42 (82%)

0.847

 

Black

4 (10%)

5 (10%)

 
 

Other

2 (5%)

4 (8%)

 

Height, cm

N

39

51

 
 

Mean ± SD

168.7 ± 11.4

169.4 ± 9.2

0.912

Weight, kg

N

41

51

 
 

Mean ± SD

85.7 ± 24.1

76.4 ± 19.2

0.049

BW ≥ 35% IBW

N

19 (46.3%)

13 (25.5%)

0.028

Causes of ARDS,a n (%)

    

Pneumonia

 

20 (49%)

15 (29%)

0.084

Toxic gas inhalation

 

0 (0%)

0 (0%)

1.000

Acute pancreatitis

 

1 (2%)

3 (6%)

0.626

Massive blood transfusion

 

5 (12%)

10 (20%)

0.404

Fat emboli

 

1 (2%)

2 (4%)

1.000

Aspiration pneumonitis

 

9 (22%)

9 (18%)

0.610

Pulmonary contusion

 

6 (15%)

12 (24%)

0.307

Postpartum ARDS

 

2 (5%)

0 (0%)

0.196

Multiple trauma

 

14 (34%)

15 (29%)

0.657

Elective or emergency surgical procedures

 

9 (22%)

20 (39%)

0.114

Patient History, n (%)

    

Preexisting steroid use

 

3 (7%)

8 (15%)

0.334

Asthma

 

4 (10%)

5 (10%)

1.000

COPD

 

6 (15%)

6 (12%)

0.761

Tobacco use

 

17 (41%)

26 (51%)

0.405

  1. aPatients may have more than one cause of ARDS. ARDS, acute respiratory distress syndrome; BW, body weight; COPD, chronic obstructive pulmonary disorder; IBW, ideal body weight; N, number; NO, nitric oxide.